Surwit E A
Department of Obstetrics and Gynecology, University of Arizona, Tucson.
J Reprod Med. 1987 Sep;32(9):657-62.
Traditionally in the United States, women have been categorized as having high-risk gestational trophoblastic disease on the basis of traditional risk criteria and have been treated in a similar fashion at most centers. Utilizing more objective and specific scoring systems allows an analysis of the most recently reported results of the treatment of high-risk patients. Identification of the "ultra-high-risk" patient allows a comparison of various therapeutic regimens at different centers. Such an analysis demonstrated the inadequacy of the traditional methotrexate/actinomycin-D/chlorambucil and modified Bagshawe regimens for these patients. Superior results have been achieved utilizing alternative regimens that include VP-16, the most effective new agent.
在美国传统上，根据传统风险标准，女性被归类为患有高危妊娠滋养细胞疾病，并且在大多数中心都以类似方式进行治疗。采用更客观、更具体的评分系统能够分析高危患者治疗的最新报告结果。识别出“超高危”患者后，可以比较不同中心的各种治疗方案。这样的分析表明，传统的甲氨蝶呤/放线菌素-D/苯丁酸氮芥和改良的巴格肖方案对这些患者并不适用。采用包括最有效的新药VP-16在内的替代方案已取得了更好的效果。
